Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952

Marijana Vujkovic; Aaron Kershenbaum; Lisa Wray; Thomas McWilliams; Shannon Cannon; Meenakshi Devidas; Linda Stork; Richard Aplenc

doi:10.1016/j.lrr.2015.05.005

Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952

Marijana Vujkovic, Aaron Kershenbaum, Lisa Wray, Thomas McWilliams, Shannon Cannon, Meenakshi Devidas, Linda Stork, Richard Aplenc

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Genetic variation in drug detoxification pathways may influence outcomes in pediatric acute lymphoblastic leukemia (ALL). We evaluated relapse risk and 24 variants in 17 genes in 714 patients in CCG-1961. Three TPMT and 1 MTR variant were associated with increased risks of relapse (rs4712327, OR 3.3, 95%CI 1.2-8.6; rs2842947, OR 2.7, 95%CI 1.1-6.8; rs2842935, OR 2.5, 95%CI 1.1-5.0; rs10925235, OR 4.9, 95%CI 1.1-25.1). One variant in SLC19A1 showed a protective effect (rs4819128, OR 0.5, 95%CI 0.3-0.9). Our study provides data that relapse risk in pediatric ALL is associated with germline variations in TPMT, MTR and SLC19A1.

Original language	English (US)
Pages (from-to)	47-50
Number of pages	4
Journal	Leukemia Research Reports
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.lrr.2015.05.005
State	Published - May 27 2015
Externally published	Yes

Keywords

Acute lymphoblastic leukemia
Folate pathway
Relapse
SNPs

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.lrr.2015.05.005

Cite this

@article{e74747ecc4d645d18d0eea0ac2610419,

title = "Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952",

abstract = "Genetic variation in drug detoxification pathways may influence outcomes in pediatric acute lymphoblastic leukemia (ALL). We evaluated relapse risk and 24 variants in 17 genes in 714 patients in CCG-1961. Three TPMT and 1 MTR variant were associated with increased risks of relapse (rs4712327, OR 3.3, 95%CI 1.2-8.6; rs2842947, OR 2.7, 95%CI 1.1-6.8; rs2842935, OR 2.5, 95%CI 1.1-5.0; rs10925235, OR 4.9, 95%CI 1.1-25.1). One variant in SLC19A1 showed a protective effect (rs4819128, OR 0.5, 95%CI 0.3-0.9). Our study provides data that relapse risk in pediatric ALL is associated with germline variations in TPMT, MTR and SLC19A1.",

keywords = "Acute lymphoblastic leukemia, Folate pathway, Relapse, SNPs",

author = "Marijana Vujkovic and Aaron Kershenbaum and Lisa Wray and Thomas McWilliams and Shannon Cannon and Meenakshi Devidas and Linda Stork and Richard Aplenc",

note = "Publisher Copyright: {\textcopyright} 2015 .",

year = "2015",

month = may,

day = "27",

doi = "10.1016/j.lrr.2015.05.005",

language = "English (US)",

volume = "4",

pages = "47--50",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952

AU - Vujkovic, Marijana

AU - Kershenbaum, Aaron

AU - Wray, Lisa

AU - McWilliams, Thomas

AU - Cannon, Shannon

AU - Devidas, Meenakshi

AU - Stork, Linda

AU - Aplenc, Richard

PY - 2015/5/27

Y1 - 2015/5/27

N2 - Genetic variation in drug detoxification pathways may influence outcomes in pediatric acute lymphoblastic leukemia (ALL). We evaluated relapse risk and 24 variants in 17 genes in 714 patients in CCG-1961. Three TPMT and 1 MTR variant were associated with increased risks of relapse (rs4712327, OR 3.3, 95%CI 1.2-8.6; rs2842947, OR 2.7, 95%CI 1.1-6.8; rs2842935, OR 2.5, 95%CI 1.1-5.0; rs10925235, OR 4.9, 95%CI 1.1-25.1). One variant in SLC19A1 showed a protective effect (rs4819128, OR 0.5, 95%CI 0.3-0.9). Our study provides data that relapse risk in pediatric ALL is associated with germline variations in TPMT, MTR and SLC19A1.

AB - Genetic variation in drug detoxification pathways may influence outcomes in pediatric acute lymphoblastic leukemia (ALL). We evaluated relapse risk and 24 variants in 17 genes in 714 patients in CCG-1961. Three TPMT and 1 MTR variant were associated with increased risks of relapse (rs4712327, OR 3.3, 95%CI 1.2-8.6; rs2842947, OR 2.7, 95%CI 1.1-6.8; rs2842935, OR 2.5, 95%CI 1.1-5.0; rs10925235, OR 4.9, 95%CI 1.1-25.1). One variant in SLC19A1 showed a protective effect (rs4819128, OR 0.5, 95%CI 0.3-0.9). Our study provides data that relapse risk in pediatric ALL is associated with germline variations in TPMT, MTR and SLC19A1.

KW - Acute lymphoblastic leukemia

KW - Folate pathway

KW - Relapse

KW - SNPs

UR - http://www.scopus.com/inward/record.url?scp=84938068311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938068311&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2015.05.005

DO - 10.1016/j.lrr.2015.05.005

M3 - Article

AN - SCOPUS:84938068311

SN - 2213-0489

VL - 4

SP - 47

EP - 50

JO - Leukemia Research Reports

JF - Leukemia Research Reports

IS - 2

ER -

Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this